Lexeo Therapeutics CEO Richard Nolan Townsend sold 3,345 shares of common stock on August 18, 2026. The sale was conducted to cover tax liabilities associated with restricted stock unit vesting, with the CEO retaining a significant stake in the company.
Lexeo CEO Sells Shares for RSU Tax Obligations
LXEOInsider TradingExecutive CompensationStock SalesBiotechnology



